Business Context and Reporting Period
This Form 8-K Current Report is filed by Conversion Labs, Inc. (not Lifemd, Inc.) for the reporting period ending November 6, 2020. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and the resignation of a former director, along with associated unregistered equity sales.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes
- Director Appointment: On November 6, 2020, the Board appointed Roberto Simon as a Director and member of the Audit Committee. Mr. Simon is currently the CFO of WEX Inc. and previously served as CFO of Revlon, Inc.
- Director Resignation: On November 10, 2020, Michael Borenstein resigned from the Board effective immediately. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Equity Issuance: The Company issued 20,000 shares of common stock to Mr. Simon as compensation for his director services. These shares were issued pursuant to an exemption under Section 4(a)(2) and/or Regulation D of the Securities Act of 1933.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. However, it details specific compensatory arrangements:
- Roberto Simon Compensation:
- One-time grant of 20,000 shares of common stock (Director Shares).
- Quarterly cash compensation of $6,000 for Audit Committee service.
- Eligibility to participate in future stock option plans.
- Michael Borenstein Departure Terms:
- Acceleration of vesting for 15,000 previously issued stock options.
- Shares underlying the options remain subject to an 180-day lock-up agreement starting November 3, 2020.
Investor Verification Checklist
- Verify the correct registrant name is Conversion Labs, Inc., as the input metadata incorrectly listed "Lifemd, Inc."
- Confirm the terms of the Director Agreement (Exhibit 10.1) regarding the 20,000 shares issued to Roberto Simon.
- Review the lock-up agreement details for Michael Borenstein's accelerated options to understand potential future selling pressure.
- Note that no financial statements or performance metrics are included in this specific filing.